NCT05119998View on ClinicalTrials.gov

A Phase I Study of IBI325 in Patients With Advanced Solid Tumor

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

July 27, 2023

Study Completion Date

August 8, 2023

Conditions
Solid Tumor
Interventions
DRUG

IBI325 + sintilimab

IBI325 + sintilimab combination does-escalation Patients will receive IBI325 and sintilimab until progressive disease, intolerability, or other reasons leading to treatment discontinuation

DRUG

IBI325

IBI325 monotherapy does-escalation Patients will receive IBI325 until progressive disease, intolerability, or other reasons leading to treatment discontinuation

Trial Locations (1)

250117

Shandong Province Cancer Hospital, Jinan

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY